Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal...

Related Keywords

United Kingdom ,Boston ,Massachusetts ,United States ,David Connolly ,Christian Roth ,Adam Daley ,Seattle Children Research Institute ,Nasdaq ,Department Of Pediatrics ,Berry Company Public Relations ,Corporate Communications ,Medicines Healthcare Products Regulatory Agency ,European Commission ,University Of Washington ,Rhythm Pharmaceuticals ,Drug Administration ,Exchange Commission ,European Union ,Rhythm Pharmaceuticals Inc ,Division Of Endocrinology ,Lancet Diabetes ,Seattle Children ,Research Institute ,About Rhythm ,Healthcare Products Regulatory Agency ,Pre Existing Nevi ,Sexual Arousal ,Suicidal Ideation ,Serious Adverse Reactions Due ,Benzyl Alcohol Preservative ,Low Birth Weight Infants ,Product Characteristics ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Markets ,